Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMY67U8)

Drug Name
Trapidil Drug Info
Synonyms
trapidil; Trapymin; Rocornal; 15421-84-8; Avantrin; Trapymine; N,N-diethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine; AR 12008; Trapidilum [INN-Latin]; UNII-EYG5Y6355E; EINECS 239-434-2; BRN 0186842; 7-Diethylamino-5-methyl-s-triazolo(1,5-a)pyrimidine; MLS000567667; EYG5Y6355E; N,N-Diethyl-5-methyl-(1,2,4)triazolo(1,5-a)pyrimidine-7-amine; (1,2,4)Triazolo(1,5-a)pyrimidin-7-amine, N,N-diethyl-5-methyl-; 5-Methyl-7-diethylamino-s-triazolo-(1,5-a)-pyrimidine; NCGC00016715-01; AR-12008; SMR000154170; SU10991
Indication
Disease Entry ICD 11 Status REF
Acute coronary syndrome BA41 Phase 4 [1]
Coronary artery disease BA80 Phase 4 [1]
Multiple myeloma 2A83 Investigative [2]
Cross-matching ID
PubChem CID
5531
ChEBI ID
CHEBI:32254
CAS Number
CAS 15421-84-8
TTD Drug ID
DMY67U8

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Platelet-derived growth factor receptor (PDGFR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [4]
Pazopanib HCl DM6U9CQ Renal cell carcinoma 2C90 Approved [5]
Intedanib DMSTA36 Colorectal cancer 2B91.Z Approved [6]
CT-102 DMB8PF3 Diabetic foot ulcer BD54 Approved [7]
TKI258 DMYLT67 Renal cell carcinoma 2C90 Phase 3 [4]
BAY-57-9352 DMVA5NS Gastric adenocarcinoma 2B72 Phase 2 [4]
X-82 DMW1NKO Age-related macular degeneration 9B75.0 Phase 2 [8]
Vorolanib DMIM1U9 Non-small-cell lung cancer 2C25 Phase 2 [9]
PMID25623274-Compound-WO2014132220C2 DMXEZWP Pulmonary arterial hypertension BB01.0 Patented [10]
PMID25623274-Compound-WO2014132220C1 DMA2IMQ Pulmonary arterial hypertension BB01.0 Patented [10]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Fibroblast growth factor receptor 3 (FGFR3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pemigatinib DM819JF Cholangiocarcinoma 2C12.10 Approved [11]
E-3810 DM42PFT Solid tumour/cancer 2A00-2F9Z Phase 3 [12]
TKI258 DMYLT67 Renal cell carcinoma 2C90 Phase 3 [4]
BMS-582664 DMDAN8H Hepatocellular carcinoma 2C12.02 Phase 3 [4]
Debio 1347 DMZW50O Solid tumour/cancer 2A00-2F9Z Phase 2 [13]
B-701 DMOMDA4 Bladder cancer 2C94 Phase 2 [14]
Recifercept DML8N3Y Achondroplasia LD24.00 Phase 2 [15]
MK-2461 DM21WBH Alzheimer disease 8A20 Phase 1/2 [16]
AEE-788 DMEOS5K Solid tumour/cancer 2A00-2F9Z Phase 1/2 [4]
Anti-FGFR3 DM6QENU Multiple myeloma 2A83 Phase 1 [17]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fibroblast growth factor receptor 3 (FGFR3) TTST7KB FGFR3_HUMAN Inhibitor [2]
Platelet-derived growth factor receptor (PDGFR) TTI2WET NOUNIPROTAC Inhibitor [3]

References

1 ClinicalTrials.gov (NCT00914420) Optical Coherence Tomography (OCT) Evaluation of Re-endothelization: A Comparison of the Intrepide Stent Versus Taxus . U.S. National Institutes of Health.
2 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
3 Osteitis fibrosa is mediated by Platelet-Derived Growth Factor-A via a phosphoinositide 3-kinase-dependent signaling pathway in a rat model for chr... Endocrinology. 2008 Nov;149(11):5735-46.
4 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
5 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
6 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
7 Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
8 National Cancer Institute Drug Dictionary (drug id 695817).
9 Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial. Chin J Cancer Res. 2021 Feb 28;33(1):103-114.
10 Evaluation of WO-2014132220, selective PDGFR inhibitors for the treatment of pulmonary arterial hypertension.Expert Opin Ther Pat. 2015 Apr;25(4):493-9.
11 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
12 E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
13 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
14 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
15 In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia. PLoS One. 2020 Dec 28;15(12):e0244368.
16 MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
17 Clinical pipeline report, company report or official report of Genentech (2011).